Rare disease biotech Bio Blast Pharma files for a $35 million IPO

By Renaissance Capital,

Shutterstock photo

Bio Blast Pharma, a clinical-stage biotech developing treatments for rare and ultra-rare genetic diseases, filed on Friday with the SEC to raise up to $35 million in an initial public offering. The Tel Aviv, Israel-based company, which was founded in 2012, plans to list on the NASDAQ but has yet to announce a ticker. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com